Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| General Motors CoGM · Entity 2958 | Director | December 31, 2025 | January 05, 2026 |
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director | July 19, 2023 | July 21, 2023 |
| PROCTER & GAMBLE CoPG · Entity 2814 | Director | October 13, 2026 | October 14, 2026 |
| Quantinuum Inc.QNT · Entity 3437 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
General Motors Co
Report date December 31, 2025 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share Units ("DSUs")SEC Table II · derivative / convertible security | Direct | 89,247 |
Reported balance
After 2025-12-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-31 · Grant · Acquired 6,172 · Balance 89,247 F1: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. |
| Deferred Share Units ("DSUs")SEC Table II · derivative / convertible security | Direct | 90,111 |
Reported balance
After 2025-12-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-31 · Grant · Acquired 864 · Balance 90,111 F2: Represents dividends accrued on DSUs in 2025 that were credited as additional DSUs at the end of the year. F1: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment.
F2: Represents dividends accrued on DSUs in 2025 that were credited as additional DSUs at the end of the year.
LENZ Therapeutics, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18 | Direct | 20,000 |
Reported balance
After 2023-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
PROCTER & GAMBLE Co
Report date October 13, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,967.634 |
Reported balance
After 2026-10-13 transaction · row 1
1 source rowRow 1 · 2026-10-13 · Grant · Acquired 1,438 · Balance 38,967.634 F1: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan.
Quantinuum Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 72,498 |
Ending reported balance
After 2026-06-05 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-04 · Grant · Acquired 5,833 · Balance 5,833 F1: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027. Row 2 · 2026-06-05 · Purchase · Acquired 66,665 · Balance 72,498 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Century Therapeutics, Inc.
Report date June 12, 2025 · Filed June 16, 2025
Section 16 reporting ended · disclosed 2021-06-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2035-06-12 | Direct | 44,000 |
Reported balance
After 2025-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 44,000 · Balance 44,000 F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2026 Filed Oct 14, 2026 19:52 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,438 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000220 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,967.634 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 18:30 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 327 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000162 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,529.634 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 09, 2026 Filed Jun 10, 2026 18:18 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 320 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000072 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,016.0703 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:31 UTC | Quantinuum Inc. QNT · Entity 3437 | PurchaseClass A Common Stock | 66,665 | $60.00 | $3,999,900.00 |
DisclosureSEC source: 0001628280-26-041633 · wk-form4_1780950710.xml · nonDerivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,498 Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:31 UTC | Quantinuum Inc. QNT · Entity 3437 | GrantClass A Common Stock | 5,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-041633 · wk-form4_1780950710.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,833 F1 · shares: Represents an award of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 18:03 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-26-000029 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,512.1482 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:36 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 864 | $0.00 | $0.00 |
DisclosureSEC source: 0001199095-26-000002 · wk-form4_1767648962.xml · derivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,111 Underlying: Common Stock · 864 shares Expires not disclosed F2 · security: Represents dividends accrued on DSUs in 2025 that were credited as additional DSUs at the end of the year. F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:36 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 6,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001199095-26-000002 · wk-form4_1767648962.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,247 Underlying: Common Stock · 6,172 shares Expires not disclosed F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 21:13 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 341 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000280 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,083.677 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2025 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 14, 2025 Filed Oct 15, 2025 19:04 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000223 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,575.9784 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 17:02 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 298 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000146 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,100.9784 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:26 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0001062993-25-011787 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 12, 2026, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 11, 2025 17:27 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0000080424-25-000054 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,658.4125 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| March 11, 2025 Filed Mar 12, 2025 17:38 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 246 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-009209 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,229.9654 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:13 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 824 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-25-000018 · wk-form4_1735942415.xml · derivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,075 Underlying: Common Stock · 824 shares Expires not disclosed F2 · security: Represents dividends accrued on DSUs in 2024 that were credited as additional DSUs at the end of the year. F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 22:13 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 7,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-25-000018 · wk-form4_1735942415.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,251 Underlying: Common Stock · 7,543 shares Expires not disclosed F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 10, 2024 Filed Dec 11, 2024 19:53 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 276 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-029120 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,858.8078 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 08, 2024 Filed Oct 9, 2024 16:02 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,309 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-025353 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,463.5277 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 10, 2024 Filed Sep 11, 2024 18:17 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 268 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-023765 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,154.5277 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:51 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0001062993-24-012907 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 20, 2025, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 20:58 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 284 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-018462 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,776.9774 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 15:57 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 263 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009938 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,384.2812 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:22 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 722 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-24-000020 · wk-form4_1704320529.xml · derivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,708 Underlying: Common Stock · 722 shares Expires not disclosed F2 · security: Represents dividends accrued on DSUs in 2023 that were credited as additional DSUs at the end of the year. . F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 22:22 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 9,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-24-000020 · wk-form4_1704320529.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,986 Underlying: Common Stock · 9,944 shares Expires not disclosed F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 18:44 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 326 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029536 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,015.9942 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 16:08 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,520 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025737 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,583.6382 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 15:49 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 296 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-024036 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,063.6382 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 21:08 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-23-043137 · doc4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 20:21 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0001062993-23-014171 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2024-06-27 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 27, 2024, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 18:56 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 311 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-018694 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,675.4716 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 14:35 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 287 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-010235 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,275.0089 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:17 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 287 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-23-000018 · wf-form4_167287059424785.xml · derivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,042 Underlying: Common Stock · 287 shares Expires not disclosed F2 · security: Represents dividends accrued on DSUs in 2022 that were credited as additional DSUs at the end of the year. F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 31, 2022 Filed Jan 4, 2023 22:17 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units ("DSUs") · Derivative | 8,076 | $0.00 | $0.00 |
DisclosureSEC source: 0001467858-23-000018 · wf-form4_167287059424785.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,755 Underlying: Common Stock · 8,076 shares Expires not disclosed F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 13, 2022 Filed Dec 14, 2022 19:07 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 292 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-027438 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,893.0213 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 15:41 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023875 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,510.3539 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 14:20 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-022433 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900.3539 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 21:38 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-22-038733 · doc4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 20:07 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 299 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017610 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,535.7621 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:22 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantStock Option (right to buy) · Derivative | 19,872 | $0.00 Strike: $8.56 | $0.00 |
DisclosureSEC source: 0001062993-22-014654 · form4.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 9, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 20:21 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 239 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008761 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,167.3631 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 22:22 UTC | General Motors Co GM · Entity 2958 | GrantDeferred Share Units · Derivative | 5,816 | $55.88 | $324,998.08 |
DisclosureSEC source: 0001467858-22-000018 · wf-form4_164133491893076.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,679 Underlying: Common Stock · 5,816 shares Expires not disclosed F1 · derivative.exercise_price: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F2 · shares: Deferred Share Units ("DSUs") were awarded pursuant to the General Motors Company Deferred Compensation Plan for Non-Employee Directors (the ("Plan"). Under the Plan, each non-employee director is required to defer one-half of the $305,000 annual retainer fee for service on the Board of Directors into DSUs and may elect to defer more. F3 · price: The price of the DSUs is the average closing price of the Company's Common Stock during the previous calendar year. F1 · derivative.exercise_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. F1 · derivative.expiration_date: Amounts credited as DSUs will be paid in cash after the non-employee director leaves the Board, valued at the average closing price of the Company's Common Stock during the quarter immediately preceding payment. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 18:47 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031064 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,865.5056 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units (RSU's) settled in common stock. Read SEC document |
| October 12, 2021 Filed Oct 14, 2021 17:30 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 1,408 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-027059 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,546.739 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. Read SEC document |
| September 14, 2021 Filed Sep 15, 2021 19:31 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 241 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-025300 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,138.739 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionSeries B Preferred Stock · Derivative | 19,763 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-027013 · doc4.xml · derivative · entry 7 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F4 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 29, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | ConversionCommon Stock | 8,126 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-027013 · doc4.xml · nonDerivative · entry 2 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:33 UTC | Century Therapeutics, Inc. IPSC · Entity 5739 | GrantOption (right to buy) · Derivative | 19,872 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000561 · edgar.xml · derivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,872 Underlying: Common Stock · 19,872 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests on the earlier of (a) June 17, 2022 or (b) the next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 15:56 UTC | PROCTER & GAMBLE Co PG · Entity 2814 | GrantCommon Stock | 260 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-019587 · form4.xml · nonDerivative · entry 1 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,841.134 F1 · price: Restricted Stock Units awarded pursuant to The Procter & Gamble 2019 Stock and Incentive Compensation Plan. F2 · balance_after: Total includes grant of dividend equivalents in the form of Restricted Stock Units. Read SEC document |
| March 17, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantStock Option (right to buy) · Derivative | 12,469 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0000899243-21-027013 · doc4.xml · derivative · entry 6 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,469 Underlying: Common Stock · 12,469 shares Expires 2031-03-16 F2 · derivative.exercise_price: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F2 · shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F5 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of March 17, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date. F2 · derivative.underlying_shares: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. F2 · balance_after: On June 21, 2021, the Issuer completed a one-for-2.432 reverse stock split of the Issuer's Common Stock ("Reverse Stock Split"). This amount has been adjusted to give effect to this Reverse Stock Split. Read SEC document |
| March 11, 2021 Filed Jul 1, 2021 23:00 UTC | LENZ Therapeutics, Inc. GRPH · Entity 6475 | GrantSeries B Preferred Stock · Derivative | 19,763 | $5.06 | $100,000.78 |
DisclosureSEC source: 0000899243-21-027013 · doc4.xml · derivative · entry 5 JIMENEZ JOSEPH · CIK 0001199095 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,763 Underlying: Common Stock · 8,126 shares Expires not disclosed F4 · derivative.exercise_price: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F1 · kind: This transaction occurred prior to the Issuer's initial public offering ("IPO") and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F4 · derivative.exercise_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. F4 · derivative.expiration_date: These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a 2.432-for-one basis into shares of the Issuer's common stock immediately upon the closing of the IPO without payment of additional consideration. The Series B Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.